DiscoverKorean Startup News[K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest
[K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest

[K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest

Update: 2025-06-20
Share

Description

https://en.wowtale.net/2025/06/16/231357/

This episode features an interview with CrossPoint Therapeutics, a Korean startup focused on addressing critical side effects in antibody-drug conjugates (ADCs). The company has developed "Stealth Body" technology, which aims to prevent adverse immune cell interactions caused by the Fc region of antibodies, a common issue in current ADC treatments that leads to severe organ damage. CrossPoint believes its technology surpasses existing solutions from leading biotech firms by maintaining antibody stability and half-life while completely silencing unwanted Fc interactions. The company is actively seeking investment to fund monkey studies, a crucial step towards global licensing deals with major pharmaceutical companies interested in safer and more effective ADCs.

Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

[K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest

[K-Startup Interview] CrossPoint Tackles Key ADC Market Issue with Fc Silencing Tech, Attracting Global Biotech Interest

WOWTALE